For Quick Alerts
For Daily Alerts

Ranbaxy facilities in India under review: Health Minister

By Religare
Ranbaxy facilities in India under review: Health Minister
Health Minister Gulam Nabi Azad has said that Ranbaxy facilities in India are being reviewed after its US arm admitted to manufacturing certain drugs not in conformity with good manufacturing practices and which are considered "adulterated" under US law.

However, in India manufacturing of drugs not in conformity with GMP is viewed as non-compliance to GMP under the said Act & Rules, he said.

The Drugs Controller General of India has been ordered to review facilities of Ranbaxy in the country to ascertain the quality of drugs manufactured for domestic market, he said.

Earlier, Ranbaxy agreed to pay the fine of USD 500 million after its US arm pleaded guilty.

Dion Global Solutions Ltd.

Read more about: ranbaxy laboratories
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more